Ming Jin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5053079/publications.pdf

Version: 2024-02-01

		1163117	1588992
8	1,502 citations	8	8
papers	citations	h-index	g-index
8	8	8	2964
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Analysis of α-synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa010.	3.3	21
2	Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer's disease brain. Acta Neuropathologica, 2018, 136, 19-40.	7.7	100
3	Decoding the synaptic dysfunction of bioactive human AD brain soluble A^2 to inspire novel therapeutic avenues for Alzheimerâ \in [™] s disease. Acta Neuropathologica Communications, 2018, 6, 121.	5.2	46
4	An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimerâ \in ^M s disease. Nature Communications, 2018, 9, 2676.	12.8	50
5	β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. Science, 2017, 357, 891-898.	12.6	341
6	Systematic analysis of time-dependent neural effects of soluble amyloid \hat{l}^2 oligomers in culture and in vivo: Prevention by scyllo-inositol. Neurobiology of Disease, 2015, 82, 152-163.	4.4	43
7	C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death. Journal of Neuroscience, 2015, 35, 10851-10865.	3.6	131
8	Soluble amyloid \hat{I}^2 -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5819-5824.	7.1	770